Carlsbad’s Ionis Pharmaceuticals struck a deal worth up to $940 million with Japan-based Ono Pharmaceutical for its medicine ...

过去一年，核酸药物市场热闹非凡，在罕见病、遗传病、乙肝、肥胖、肿瘤等领域都展现出治疗潜力，吸引众多药企布局。据统计，2024年该领域潜在交易总金额达到208亿美元。 日前，ASO龙头Ionis ...

Ono Pharmaceutical Co. Ltd. struck a licensing deal with Ionis Pharmaceuticals Inc. for sapablursen, which is in phase II trials for polycythemia vera. Under terms, Osaka, Japan-based Ono gains an ...

(Carlsbad, CA,U.S.; CEO, Brett P. Monia, Ph.D.; “Ionis”) for sapablursen, an investigational RNA-targeted medicine for the treatment of polycythemia vera (PV). Sapablursen is currently being evaluated ...

Ionis Pharmaceuticals IONS signed a license agreement with Japan-based Ono Pharmaceutical. Per the terms, Ono has acquired exclusive global rights from IONS to develop and market sapablursen, an ...

Ionis will receive $280M upfront from Ono ... Sapablursen, an investigational RNA therapy for polycythemia vera, is in a fully enrolled Phase 2 trial. Pelosi’s latest AI pick skyrocketed ...

Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) and Ono Pharmaceutical Co., Ltd (Ono), today announced that the two companies have entered into a license a ...

Ionis Pharmaceuticals licensed out its investigational antisense oligonucleotide sapablursen to Ono Pharmaceutical on Tuesday, giving the Japanese firm exclusive global rights to develop and ...